| abstract |
A lentiviral vector comprising a therapeutic gene that inhibits intraocular cellular proliferation or intraocular neovascularization is used in the manufacture of a medicament for inhibiting intraocular cellular proliferation or intraocular neovascularization an individual having an ocular disease. Preferably the ocular disease is selected from age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, glaucoma and proliferative vitreoretinopathy and the gene is selected from constitutively active form of the retinoblastoma gene, p16 gene, p21 gene, tissue inhibitor of metalloproteinase(TIMP)-1, TIMP-2, TIMP-3, TIMP-4, endostatin, angiostatin, endostatin XVIII, endostatin XV, the C-terminal hemopexin domain of matrix metalloproteinase-2, the kringle 5 domain of human plasminogen, a fusion protein of endostatin and angiostatin, a fusion protein of endostatin and the kringle 5 domain of human plasminogen, the monokine-induced by interferon-gamma (Mig), the interferon-alpha inducible protein 10 (IP10), a fusion protein of Mig and IP10, soluble FLT-1 (fms-like tyrosine kinase 1 receptor), and kinase insert domain receptor (KDR). |